09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
Software; software and hardware for diagnosing, monitoring,
measuring, calculating, analysing and displaying airway
inflammation and respiratory status; software and hardware
for analysing, storing, organising, categorising, tracking,
displaying and retrieving data regarding airway inflammation
and respiratory status; software and hardware for analysing,
storing, organising, categorising, tracking, displaying and
retrieving data from medical devices. Medical devices; medical apparatus and instruments; medical
apparatus for sampling of gases in human organs and for
control of pulmonary functionality; medical devices for
controlling the exhalation of oxygen in breath; medical
devices being containers for the storage of exhaled breath
samples; medical devices, namely, respiratory filters and
nozzles for use in sampling exhalation; medical devices,
namely, containers for sampling and storing of gas tests.
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
Computer hardware and recorded software sold as a unit for diagnosing, monitoring, measuring, calculating, analysing and displaying airway inflammation and respiratory status; Computer hardware and recorded software sold as a unit for analysing, storing, organising, categorising, tracking, displaying and retrieving data regarding airway inflammation and respiratory status; Computer hardware and recorded software sold as a unit for analysing, storing, organising, categorising, tracking, displaying and retrieving data from medical devices Medical apparatus for sampling of gases in human organs and for control of pulmonary functionality; medical devices for controlling the exhalation of oxygen in breath; medical devices being containers for the storage of exhaled breath samples; medical devices, namely, respiratory filters and nozzles for use in sampling exhalation for medical purposes; medical devices, namely, containers for sampling and storing of medical gas tests
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
Software and hardware for diagnosing, monitoring, measuring,
calculating, analysing and displaying airway inflammation
and respiratory status; software and hardware for analysing,
storing, organising, categorising, tracking, displaying and
retrieving data regarding airway inflammation and
respiratory status; software and hardware for analysing,
storing, organising, categorising, tracking, displaying and
retrieving data from medical devices. Medical devices; medical apparatus and instruments; medical
apparatus for sampling of gases in human organs and for
control of pulmonary functionality; medical devices for
controlling the exhalation of oxygen in breath; medical
devices being containers for the storage of exhaled breath
samples; medical devices, namely, respiratory filters and
nozzles for use in sampling exhalation; medical devices,
namely, containers for sampling and storing of gas tests.
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
Computer hardware and recorded software sold as a unit for diagnosing, monitoring, measuring, calculating, analysing and displaying airway inflammation and respiratory status; computer hardware and recorded software sold as a unit for analysing, storing, organising, categorising, tracking, displaying and retrieving data regarding airway inflammation and respiratory status; computer hardware and recorded software sold as a unit for analysing, storing, organising, categorising, tracking, displaying and retrieving data from medical devices Medical apparatus for sampling of gases in human organs and for control of pulmonary functionality; medical devices for controlling the exhalation of oxygen in breath; medical devices being containers for the storage of exhaled breath samples; medical devices, namely, respiratory filters and nozzles for use in sampling exhalation; medical devices, namely, containers for sampling and storing of medical gas tests
5.
JAPANESE POLLEN ALLERGEN PEPTIDES FOR PREVENTING OR TREATING ALLERGY
A polypeptide or a pharmaceutically acceptable salt thereof and pharmaceutical formulations of at least three polypeptidesor salts thereof are provided which may be used for preventing or treating allergy to Japanese Cedar and/or Japanese Cypress pollen.
A process for preparing crystalline particles of an active principal in the presence of ultrasonic irradiation that comprises contacting a solution of a solute in a solvent in a first flowing stream with an anti-solvent in a second flowing stream causing the mixing thereof, wherein the flow rate ratio of the anti-solvent: solvent is higher than 20:1, and collecting crystals that are generated.
B01J 19/10 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage utilisant des vibrations de fréquences audibles ou des ultrasons
B01J 2/02 - Procédés ou dispositifs pour la granulation de substances, en généralTraitement de matériaux particulaires leur permettant de s'écouler librement, en général, p. ex. en les rendant hydrophobes par division du produit liquide en gouttelettes, p. ex. par pulvérisation, et solidification des gouttelettes
B01J 2/18 - Procédés ou dispositifs pour la granulation de substances, en généralTraitement de matériaux particulaires leur permettant de s'écouler librement, en général, p. ex. en les rendant hydrophobes par utilisation d'un vibrateur
B01J 19/18 - Réacteurs fixes avec éléments internes mobiles
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and veterinary preparations and substances;
pharmaceutical and veterinary preparations and substances
for the testing, diagnosis and treatment of allergies,
autoimmune disease, transplant rejection or immunodeficiency
disorders; reagent kits for testing and diagnosing
allergies, autoimmune disease, transplant rejection or
immunodeficiency disorders; vaccines.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and veterinary preparations and substances;
pharmaceutical and veterinary preparations and substances
for the testing, diagnosis and treatment of allergies,
autoimmune disease, transplant rejection or immunodeficiency
disorders; reagent kits for testing and diagnosing
allergies, autoimmune disease, transplant rejection or
immunodeficiency disorders; vaccines.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmaceutical and veterinary preparations; vaccines. Surgical, medical and veterinary apparatus and instruments;
parts and fittings for the aforesaid goods. Scientific research for medical purposes; medical and
pharmacological research services; research and development
in the pharmaceutical and biotechnology fields; providing
medical and scientific research information in the fields of
pharmaceutical and clinical trials; clinical trials;
information, advisory and consultancy services relating to
the aforesaid.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and veterinary preparations and substances; pharmaceutical and veterinary preparations and substances for the testing, diagnosis and treatment of allergies, autoimmune disease, transplant rejection or immunodeficiency disorders; reagent kits for testing and diagnosing allergies, autoimmune disease, transplant rejection or immunodeficiency disorders; vaccines.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and veterinary preparations and substances; pharmaceutical and veterinary preparations and substances for the testing, diagnosis and treatment of allergies, autoimmune disease, transplant rejection or immunodeficiency disorders; reagent kits for testing and diagnosing allergies, autoimmune disease, transplant rejection or immunodeficiency disorders; vaccines.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical and veterinary preparations and substances; pharmaceutical and veterinary preparations and substances for the testing, diagnosis and treatment of allergies, autoimmune disease, transplant rejection or immunodeficiency disorders; reagent kits for testing and diagnosing allergies, autoimmune disease, transplant rejection or immunodeficiency disorders; vaccines.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Pharmaceutical preparations for testing, diagnosis and treatment of allergies, autoimmune disease, transplant rejection and immunodeficiency disorders; veterinary pharmaceutical preparations for testing, diagnosis and treatment of allergies, autoimmune disease, transplant rejection and immunodeficiency disorders; Vaccines for human and veterinary use; Surgical, medical and veterinary apparatus and instruments, namely, kits comprised of pharmaceutical preparations, reagents and chemicals for testing, diagnosing and treating allergies and other immunodeficiency disorders. (1) Pharmacological research services; Research and development in the pharmaceutical and biotechnology fields; Providing medical and scientific research information in the fields of pharmaceutical and clinical trials; Conducting clinical trials; information, advisory and consultancy services relating to the aforesaid.
15.
JAPANESE CEDAR PEPTIDE FOR PREVENTING OR TREATING ALLERGY
A polypeptide which may be used for preventing or treating allergy to Japanese Cedar and/or Japanese Cypress pollen, is up to 30 amino acids in length, and comprises (I) the amino acid sequence: DLKIKLRRTIEAEGIP(SEQ ID NO: 1; Cry26); or(II)a T cell epitope-containing variant sequence which is a said amino acid sequence (I) having up to seven amino acid modifications, each of which is independently a deletion, substitution or insertion.
Pharmaceutical formulations,which may be used for preventing or treating allergy to moulds of the Alternaria and/or Cladosporiumgenus, comprising a pharmaceutically acceptable carrier or diluent and a polypeptide or a pharmaceutically acceptable salt thereof selected from at least three of: (a)a polypeptide comprising the amino acid sequence of WSWKIGPAIATGNT(Alt28; SEQ ID NO: 101) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (b)a polypeptide comprising the amino acid sequence of KYRRVVRAGVKVAQTAR(Alt34A; SEQ ID NO: 107) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (c) a polypeptide comprising the amino acid sequence of KYAGVFVSTGTLGGG (SEQ ID NO: 112) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (d)a polypeptide comprising the amino acid sequence of AEVYQKLKALAKKTYGQ(Alt13A; SEQ ID NO: 83) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (e)a polypeptide comprising the amino acid sequence of SLGFNIKATNGGTLD(Alt01A; SEQ ID NO: 60)or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (f) a polypeptide comprising the amino acid sequence of SAKRMKVAFKLDIEK(Alt06; SEQ ID NO: 72) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (g)a polypeptide comprising the amino acid sequence of DITYVATATLPNYCR(SEQ ID NO: 111) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; and (h)a polypeptide comprising the amino acid sequence of GWGVMVSHRSGET(Alt14;SEQ ID NO: 84) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; wherein a T cell epitope-containing variant sequence of a said amino acid sequence is said amino acid sequence having up to seven amino acid modifications, each of which is independently a deletion, substitution or insertion, and each polypeptide is up to 30 amino acids in length.
Polypeptides which may be used for preventing or treating allergy to moulds of the Cladosporium and/or Alternaria genus, have up to 30 amino acids in length and comprise: (I) the amino acid sequence: (a) GGYKAAVRPTMLE (SEQ ID NO : 35; Cla35), (b) AE V YQKLK SLTKK (SEQ ID NO: 31; Clal6), (c) VAITYASRAQGAE (SEQ ID NO: 32; Cla25), (d) GHHFKERGTGSLVIT (SEQ ID NO: 33; Cla26), or (e) ANYTQTKTVSIRL (SEQ ID NO: 34; Cla29); or (II) a T cell epitope-containing variant sequence which is a said amino acid sequence (I) having up to six amino acid modifications, each of which is independently a deletion, substitution or insertion.
The present invention relates to a hydrochloride salt of a peptide consisting of the sequence of CPAVKRDVDLFLT (SEQ ID NO: 1) as well as its combinations with other peptides for immunosuppressive purposes.
The present invention relates to compositions comprising peptides for preventing or treating allergy to birch, and in particular to optimal combinations of peptides for preventing or treating said allergy.
The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.
The present invention relates to compositions comprising peptides for preventing or treating allergy to birch, and in particular to optimal combinations of peptides for preventing or treating said allergy.
This invention provides a process for increasing the crystallinity of at least one solid material which is less than 100% crystalline, comprising contacting said solid material with solvent in which the solid material is insoluble or poorly soluble (a non-solvent); and applying ultrasound to the solid material when in contact with said non-solvent.
B32B 5/16 - Produits stratifiés caractérisés par l'hétérogénéité ou la structure physique d'une des couches caractérisés par le fait qu'une des couches est formée de particules, p. ex. de copeaux, de fibres hachées, de poudre
C30B 29/60 - Monocristaux ou matériaux polycristallins homogènes de structure déterminée caractérisés par leurs matériaux ou par leur forme caractérisés par la forme
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.
The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides.
The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.
A process for preparing an emulsion or a dispersion comprising crystalline particles of at least one active principal that comprises contacting a solution of at least one solute in a solvent or mixture of solvents in a first flowing stream with a non-solvent in a second flowing stream wherein the non-solvent and solvent are not miscible with each other, so as to form an emulsion or a dispersion. Super saturation is brought about by suitable means, and the emulsion or dispersion is subjected to ultrasonic irradiation to mediate crystal nucleation.
B01J 19/10 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage utilisant des vibrations de fréquences audibles ou des ultrasons
B01J 2/06 - Procédés ou dispositifs pour la granulation de substances, en généralTraitement de matériaux particulaires leur permettant de s'écouler librement, en général, p. ex. en les rendant hydrophobes par division du produit liquide en gouttelettes, p. ex. par pulvérisation, et solidification des gouttelettes en milieu liquide
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
B01J 2/18 - Procédés ou dispositifs pour la granulation de substances, en généralTraitement de matériaux particulaires leur permettant de s'écouler librement, en général, p. ex. en les rendant hydrophobes par utilisation d'un vibrateur
The present invention relates to the use of a non-reducing carbohydrate or carbohydrate derivative and at least one agent which inhibits dimer formation in a freeze-dried composition comprising at least one peptide that contains a free cysteine residue, to provide a freeze-dried composition with improved long-term storage stability.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The present invention relates to compositions for preventing or treating allergy to ragweed by tolerisation. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, Amb a 1. The invention also relates to products, vectors and formulations which may be used to provide polypeptides of the invention in combination. The invention further relates to in vitro methods for determining whether T cells recognize a polypeptide of the invention, and for determining whether an individual has or is at risk of a condition characterized by allergic symptoms in response to a ragweed allergen.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
30.
T-CELL ANTIGEN PEPTIDE FROM ALLERGEN FOR STIMULATION OF IL-10 PRODUCTION
A first or second polypeptide for use in a method of treating or preventing a disorder by tolerisation, wherein said method comprises administration of the first and second polypeptide; and wherein both first and second polypeptides: i) are of 7 to 30 amino acids in length; ii) comprise at least one MHC Class Il-binding T cell epitope; and iii) are a fragment of a protein allergen or a homologous variant of said fragment; wherein said first polypeptide induces the release of an amount of IL-10 that is greater than the amount of IL-10 released in response to the whole protein allergen from which the first polypeptide derives; wherein said disorder is characterised by an inappropriate immune response to the protein allergen from which the second polypeptide derives.
A process for preparing crystalline particles of an active principal in the presence of ultrasonic irradiation that comprises contacting a solution of a solute in a solvent in a first flowing stream with an anti-solvent in a second flowing stream causing the mixing thereof, wherein the flow rate ratio of the anti-solvent: solvent is higher than 20:1, and collecting crystals that are generated.
B01J 19/10 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage utilisant des vibrations de fréquences audibles ou des ultrasons
The present invention relates to compositions comprising peptides for preventing or treating the development of inhibitors in patients with haemophilia, in particular certain peptides and / or peptide fragments derived from factor VIII.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 4/06 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant de champignons
C07K 4/10 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant de végétaux
C07K 4/12 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'animauxPeptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés provenant d'humains
C07K 7/00 - Peptides ayant de 5 à 20 amino-acides dans une séquence entièrement déterminéeLeurs dérivés
The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
The present invention relates to soluble peptides comprising T cell epitopes and methods for engineering insoluble peptides comprising T cell epitopes to improve solubility.
The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides.
The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides.
The invention provides an in vitro method of determining whether an individual is at risk of, or undergoing, graft damage or rejection of immune origin and/or damage of immune origin to non-graft tissue using polypeptides derived from a major histocompatibility complex (MHC) class I human leukocyte antigen (HLA), such as HLA-A2, and derivatives or analogues thereof.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
